WS
ACRS icon

Wedbush Securities’s Aclaris Therapeutics ACRS Stock Holding History

Wedbush Securities’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14,000
Closed -$15K – 956
2020
Q1 		$15K Buy
+14,000
New +$19.1K ﹤0.01% 867

Other funds holding ACRS

MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wedbush Securities's ACRS Position: Q2 2020 in Review

Wedbush Securities sold out of Aclaris Therapeutics (ACRS) in Q2 2020, closing a stake of 14,000 shares — an estimated $15K sold.

Wedbush Securities first reported a position in ACRS in Q1 2020 and held it in 1 quarter. The position peaked at $15K in Q1 2020. 62 funds tracked by Wall St. Rank hold ACRS as of Q2 2020.

  • Wedbush Securities reported no remaining Aclaris Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Wedbush Securities sold 14,000 Aclaris Therapeutics shares in Q2 2020, an estimated $15K.
  • Wedbush Securities first reported a position in Aclaris Therapeutics in Q1 2020 and held it in 1 quarter.
  • Wedbush Securities's Aclaris Therapeutics position peaked at $15K in Q1 2020.
  • 62 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2020.

Based on Wedbush Securities's 13F filing for Q2 2020, filed 16 Jul 2020.